Myomo (MYO) Expected to Announce Earnings on Wednesday

Myomo (NYSEAMERICAN:MYO) is anticipated to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Myomo to post earnings of ($0.10) per share and revenue of $10.3520 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Myomo Price Performance

Shares of MYO stock traded up $0.07 during trading hours on Monday, reaching $1.06. The company had a trading volume of 20,764 shares, compared to its average volume of 577,336. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.36 and a current ratio of 2.73. The stock has a fifty day moving average of $1.13 and a 200-day moving average of $0.92. The company has a market capitalization of $41.15 million, a price-to-earnings ratio of -2.96 and a beta of 1.50. Myomo has a 12-month low of $0.60 and a 12-month high of $2.02.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets upped their target price on Myomo from $9.50 to $10.00 and gave the company a “buy” rating in a report on Monday, June 8th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $7.50.

Insider Buying and Selling at Myomo

In related news, Director Thomas F. Kirk bought 43,401 shares of the stock in a transaction on Monday, May 18th. The stock was bought at an average price of $0.91 per share, with a total value of $39,494.91. Following the completion of the purchase, the director directly owned 628,863 shares in the company, valued at $572,265.33. This represents a 7.41% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Joseph M. Jr. Manko purchased 170,830 shares of Myomo stock in a transaction dated Thursday, May 14th. The stock was bought at an average cost of $0.86 per share, for a total transaction of $146,913.80. Following the completion of the purchase, the director directly owned 2,279,408 shares in the company, valued at approximately $1,960,290.88. This trade represents a 8.10% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders bought 341,205 shares of company stock worth $317,748. Corporate insiders own 12.14% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE lifted its stake in Myomo by 93.6% during the 3rd quarter. Bank of America Corp DE now owns 30,412 shares of the company’s stock worth $27,000 after acquiring an additional 14,705 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Myomo by 103.1% during the fourth quarter. Wells Fargo & Company MN now owns 38,707 shares of the company’s stock worth $35,000 after purchasing an additional 19,646 shares in the last quarter. Invesco Ltd. purchased a new position in shares of Myomo in the second quarter valued at approximately $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Myomo in the second quarter valued at approximately $38,000. Finally, Jane Street Group LLC acquired a new position in shares of Myomo in the fourth quarter valued at approximately $64,000. 44.99% of the stock is currently owned by hedge funds and other institutional investors.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.